New gene mutation involved in familial thyroid cancers identified

Researchers from Penn State College of Medicine identified a new gene mutation that may cause a type of familial thyroid cancer. Dr. Darrin Bann, an otolaryngology resident at the College of Medicine and lead author of the study, said that this mutation is the first and only mutation associated with familial thyroid cancer to be identified in a gene that is primarily expressed in the thyroid gland.

According to the researchers, people who have a first degree relative with thyroid cancer have a two to five-fold increase of developing the disease themselves. Identifying this mutation has helped the researchers understand why this form of cancer is more inheritable than other cancers. They published the study results in Cancer Research.

Thyroid cancer is common and on the rise, and hereditary non-medullary thyroid cancers account for six to ten percent of cases. Prior to this study, there was not much data to explain why this type of cancer was highly heritable."

Dr. Darrin Bann, otolaryngology resident at Penn State College of Medicine

The researchers identified a family consisting of eight thyroid cancer patients across four generations. They used next generation sequencing, which can provide a full 'picture' of a person's genetic makeup in less than a day, to examine every gene in the genome for all of the thyroid cancer patients in the family. When analyzing the data, they discovered all the family members with thyroid cancer had a mutation in a gene called DUOX2 – a rare mutation that occurs once in every 138,000 members of the general population.

The DUOX2 gene provides information for the creation of a protein called dual oxidase 2, which produces hydrogen peroxide and is found at high levels in the thyroid gland. After performing a series of biochemical analyses on the protein with the mutation, they were able to determine that the mutated version produced more hydrogen peroxide, rather than stopping the production of the chemical.

Hydrogen peroxide is used in the final stages of thyroid hormone production, but the researchers believe the excess may cause additional gene mutations – which may increase the risk of thyroid cancer.

"Hydrogen peroxide can harm genetic material through a process called oxidative damage," Bann said. "This may be a common theme underlying genetic risk for developing thyroid cancer. If we can identify more mutations that increase risk for oxidative damage, we may be able to develop preventative strategies – including treatments with antioxidants."

Based on their findings, the researchers decided to see if DUOX2 was related to other genetic mutations associated with non-medullary thyroid cancers. They found that some individuals with sporadic thyroid cancers had a mutation that increased the amount of DUOX2 in the thyroid gland. These findings suggest to the researchers that dysregulation of hydrogen peroxide may be the cause of other genetic mutations associated with thyroid cancers.

In the future, Bann hopes knowledge of this mutation can help create new models for studying thyroid cancer in the lab and the development of prevention strategies. While previous mutations have been identified in families with thyroid cancer, Bann says the DUOX2 mutation is the only one that connects directly to thyroid tissue.

"The individuals with thyroid cancer in the family we studied had a mutation in a gene that is related to thyroid tissue," Bann said. "Finding other families and individuals with this mutation will be essential for confirming our findings."

Source:
Journal reference:

Bann, D.V., et al. (2019) Genetic Variants Implicate Dual Oxidase-2 (DUOX2) in Familial and Sporadic Non-Medullary Thyroid Cancer. Cancer Research. doi.org/10.1158/0008-5472.CAN-19-0721.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Polyplus-transfection expands GMP portfolio to provide additional flexibility for gene and cell therapy developers